These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26014946)

  • 1. A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients.
    Carlier M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4689-94. PubMed ID: 26014946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
    Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
    Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
    De Bus L; Denys W; Catteeuw J; Gadeyne B; Vermeulen K; Boelens J; Claeys G; De Waele JJ; Decruyenaere J; Depuydt PO
    Intensive Care Med; 2016 Jun; 42(6):1029-39. PubMed ID: 27025939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis.
    Hartman SJF; Boeddha NP; Ekinci E; Koch BCP; Donders R; Hazelzet JA; Driessen GJ; de Wildt SN
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1255-1260. PubMed ID: 30968258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Antibiotics in Sub-Saharan African Patient Populations: A Systematic Review.
    Bos JC; van Hest RM; Prins JM
    Ther Drug Monit; 2017 Aug; 39(4):387-398. PubMed ID: 28703719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
    Sinnollareddy MG; Roberts MS; Lipman J; Roberts JA
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):489-96. PubMed ID: 22519600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.
    Carrié C; Petit L; d'Houdain N; Sauvage N; Cottenceau V; Lafitte M; Foumenteze C; Hisz Q; Menu D; Legeron R; Breilh D; Sztark F
    Int J Antimicrob Agents; 2018 Mar; 51(3):443-449. PubMed ID: 29180280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients.
    Abdulla A; Ewoldt TMJ; Purmer IM; Muller AE; Gommers D; Endeman H; Koch BCP
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):359-368. PubMed ID: 33463382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment.
    Chiriac U; Frey OR; Roehr AC; Koeberer A; Gronau P; Fuchs T; Roberts JA; Brinkmann A
    Medicine (Baltimore); 2021 Jun; 100(22):e26253. PubMed ID: 34087915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
    Mohd Hafiz AA; Staatz CE; Kirkpatrick CM; Lipman J; Roberts JA
    Minerva Anestesiol; 2012 Jan; 78(1):94-104. PubMed ID: 21730935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy.
    Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2171-2175. PubMed ID: 30120647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens.
    Fuchs A; Li G; van den Anker JN; Bielicki J
    Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients.
    Roberts JA; Choi GY; Joynt GM; Paul SK; Deans R; Peake S; Cole L; Stephens D; Bellomo R; Turnidge J; Wallis SC; Roberts MS; Roberts DM; Lassig-Smith M; Starr T; Lipman J
    BMC Infect Dis; 2016 Mar; 16():103. PubMed ID: 26932762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic issues for antibiotics in the critically ill patient.
    Roberts JA; Lipman J
    Crit Care Med; 2009 Mar; 37(3):840-51; quiz 859. PubMed ID: 19237886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.